能動埋め込み型医療機器の世界市場規模：製品タイプ、エンドユーザー、地域別、2026-2032年

能動埋め込み型医療機器市場の評価、2026-2032年

高度で高品質な医療機器に対する需要の増加、製品設計やエンジニアリングの複雑化、デジタル技術の幅広い利用は、能動埋め込み型医療機器市場を前進させる重要な促進要因です。Verified Market Research社のアナリストによると、能動埋め込み型医療機器市場の予測評価額は508億米ドルで、2024年には約270億米ドルを下回る。

この需要の急増により、市場は2026年から2032年にかけてCAGR 8.22％で成長します。

能動埋め込み型医療機器市場定義/概要

能動埋め込み型医療機器は、手術中に自然の開口部から体内に挿入されます。手術後、デバイスはその場所に留まり、外部の電気エネルギーまたは別の供給源から電力を供給されます。能動埋め込み型医療機器は、米国食品医薬品局（FDA）によりハイリスクに分類されています。

さらに、能動埋め込み型医療機器の中には、心臓再同期療法機器、薬剤注入ポンプ、埋め込み型除細動器、埋め込み型ペースメーカー、人工内耳、埋め込み型除細動器などがあります。心臓血管機器、パーキンソン病、てんかん、痙縮、聴覚障害や視覚障害を含む多くの病気は、これらの機器によって著しく管理されています。

能動埋め込み型医療機器の採用を促進する要因は？

医療技術の進歩、慢性疾患の増加、高齢化、低侵襲治療へのシフト、予防医療と個別化医療の重視などにより、能動埋め込み型医療機器市場は勢いを増しています。ペースメーカー、神経刺激装置、植え込み型ドラッグデリバリーシステムなどのこれらの機器は、高度なセンサー、電子機器、ソフトウェアアルゴリズムを使用して、生理学的パラメーターをモニターし、治療的介入を行い、患者の転帰を改善します。これらの機器に対する需要は、慢性疾患や加齢に関連した疾患の有病率が上昇し、慢性症状を管理しヘルスケアコストを削減するための長期的な治療ソリューションが必要とされていることが背景にあります。

さらに高齢化社会では、高齢者が自立して機能性を維持できるような医療介入も求められています。低侵襲手術や外来治療へのシフトも、継続的モニタリング、早期介入、個別化治療アプローチを可能にする能動埋め込み型医療機器への需要を促進しています。世界中のヘルスケアシステムが慢性疾患の予防的管理と疾病予防を優先しているため、個別化ケアと遠隔モニタリングをサポートする能動埋め込み型医療機器に対する需要は増加し、市場拡大の原動力になると予想されます。

能動埋め込み型医療機器市場の課題は？

能動埋め込み型医療機器市場は、厳しい規制要件、高コスト、安全性への懸念、相互運用性の問題など、いくつかの課題に直面しています。FDAやEMAなどの規制機関は、安全性と有効性を確保するために、大規模な臨床試験、市販前評価、市販後サーベイランスを義務付けています。規制当局の承認が遅れると、市場投入までの期間が長期化し、技術革新が妨げられ、開発コストが増大するため、市場の成長が制限されます。また、能動埋め込み型医療機器の高額なコストは、患者やヘルスケアシステムにとって経済的な障壁となります。厳格な試験、品質保証、規制遵守の必要性がコスト全体を押し上げ、市場導入と革新的治療への患者のアクセスを制限しています。

さらに、機器の安全性、信頼性、長期的性能に関する懸念も、メーカーやヘルスケアプロバイダーに課題を突きつけています。機器の誤作動、部品の不具合、副作用などの問題は、患者の健康と安全にリスクをもたらす可能性があります。バッテリー寿命や機器の劣化といった長期的な性能の問題は、患者の転帰に影響を与え、ヘルスケアコストを増加させる可能性があります。相互運用性と接続性の問題も、医療システムや電子カルテ（EHR）に能動埋め込み機器を統合するための課題となっています。

目次

第1章 能動埋め込み型医療機器の世界市場導入

• 市場概要
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• バリデーション
• 一次資料
• データソース一覧

第4章 能動埋め込み型医療機器の世界市場展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析

第5章 能動埋め込み型医療機器の世界市場：製品タイプ別

• 概要
• 埋め込み型除細動器
• 補助人工心臓
• 埋め込み型心臓モニター
• 埋め込み型心臓ペースメーカー
• 埋め込み型補聴器
• 神経刺激装置
• その他

第6章 能動埋め込み型医療機器の世界市場：エンドユーザー別

• 概要
• 病院
• 診療所
• 外来手術センター
• 多科目センター
• その他

第7章 能動埋め込み型医療機器の世界市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他アジア太平洋地域
• 中東・アフリカ
• ラテンアメリカ

第8章 能動埋め込み型医療機器の世界市場の競合情勢

• 概要
• 各社の市場ランキング
• 主な発展戦略

第9章 企業プロファイル

• Boston Scientific Corporation
• Medtronic Plc
• William Demant Holding A/S
• Abbott Laboratories
• BIOTRONIK SE & Co. KG
• Cochlear Limited
• MED-EL
• Sonova Holding AG
• Nurotron Biotechnology Co., Ltd.
• LivaNova PLC

第10章 付録

• 関連調査

Active Implanted Medical Devices Market Valuation - 2026-2032

The increasing demand for advanced and high-quality medical devices, rising complexity in product design and engineering, and wide usage of digital technology are significant drivers propelling the active implanted medical devices market forward. According to the analyst from Verified Market Research, the active implanted medical devices market has a valuation of USD 50.8 Billion over the forecast subjugating around USD 27 Billion in 2024.

This surge in demand enables the market to grow at a CAGR of 8.22% from 2026 to 2032.

Active Implanted Medical Devices Market: Definition/ Overview

Active implantable medical devices are inserted into the body through a natural opening during surgery, either fully or partially. After the process, the device remains in that place and is powered by external electrical energy or another source. Active implantable medical devices are classified as high-risk by the United States Food and Drug Administration (FDA).

Furthermore, among the active implantable medical devices are cardiac resynchronization therapy devices, drug infusion pumps, implantable defibrillators, implantable pacemakers, cochlear implants, and implantable defibrillators. Numerous ailments, including cardiovascular devices, Parkinson's disease, epilepsy, spasticity, and individuals with hearing or vision impairment, are significantly managed by these devices.

Which are the Drivers Encouraging the Adoption of Active Implanted Medical Devices?

The active implanted medical devices market is gaining momentum due to advancements in medical technology, the rise of chronic diseases, the aging population, the shift towards minimally invasive procedures, and the focus on preventive and personalized medicine. These devices, such as pacemakers, neurostimulators, and implantable drug delivery systems, use advanced sensors, electronics, and software algorithms to monitor physiological parameters, deliver therapeutic interventions, and improve patient outcomes. The demand for these devices is driven by the rising prevalence of chronic diseases and age-related conditions, which require long-term therapeutic solutions to manage chronic conditions and reduce healthcare costs.

Furthermore, the aging population also demands medical interventions that enable older adults to maintain independence and functionality. The shift towards minimally invasive procedures and outpatient care is also driving the demand for active implanted medical devices, which enable continuous monitoring, early intervention, and personalized treatment approaches. As healthcare systems worldwide prioritize proactive management of chronic conditions and disease prevention, the demand for active implanted devices that support personalized care and remote monitoring is expected to increase, driving market expansion.

What are the Challenges in the Active Implanted Medical Devices Market?

The active implanted medical devices market faces several challenges, including stringent regulatory requirements, high costs, safety concerns, and interoperability issues. Regulatory agencies like the FDA and EMA require extensive clinical trials, pre-market evaluations, and post-market surveillance to ensure safety and efficacy. Delays in regulatory approval prolong the time to market, hinder innovation, and increase development costs, limiting market growth. The high cost of active implanted medical devices also poses financial barriers for patients and healthcare systems. The need for rigorous testing, quality assurance, and regulatory compliance adds to the overall cost, limiting market adoption and patient access to innovative treatments.

Furthermore, concerns about device safety, reliability, and long-term performance also pose challenges for manufacturers and healthcare providers. Issues such as device malfunction, component failure, and adverse reactions can pose risks to patient health and safety. Long-term performance issues, such as battery life and device degradation, can impact patient outcomes and increase healthcare costs. Interoperability and connectivity issues also present challenges for the integration of active implanted devices into healthcare systems and electronic health records (EHRs).

Category-Wise Acumens

How Cardioverter Defibrillators helps in the growth of the Active Implanted Medical Devices Market?

According to VMR analysis, the Cardioverter defibrillators (ICDs) segment is estimated to dominate the market during the forecast period due to their effectiveness in treating life-threatening cardiac arrhythmias and sudden cardiac arrest. These devices continuously monitor the heart's rhythm and deliver electrical shocks to restore normal heart rhythm when dangerous arrhythmias occur. The increasing prevalence of cardiovascular diseases and related risk factors worldwide is driving the growth of ICDs. Technological advancements in ICD technology, such as dual-chamber pacing, cardiac resynchronization therapy (CRT), and remote monitoring capabilities, are driving the adoption of these devices. These advancements improve patient outcomes, reduce the risk of inappropriate shocks, and enable healthcare providers to remotely monitor patients' cardiac status and device performance.

Furthermore, the growing indications for ICD therapy and awareness of sudden cardiac death risk factors are driving the demand for these devices in diverse patient populations. As clinical guidelines evolve and awareness of the benefits of ICD therapy increases among healthcare providers and patients, the market for these devices is expected to grow. Emerging markets, such as. Asia-Pacific, Latin America, and the Middle East present significant opportunities for market growth. Manufacturers are expanding their presence, investing in research and development, and collaborating with local healthcare providers to address unmet medical needs. In summary, cardioverter defibrillators are essential for the growth of the active implanted medical devices market.

Which Factors are Influencing the Growth of the Market in Hospitals?

The hospital segment is estimated to dominate the active implanted medical devices market influenced by several factors. Advancements in medical technology have led to the development of sophisticated devices that offer targeted and personalized treatment options for various medical conditions. These devices, such as pacemakers, implantable cardioverter defibrillators (ICDs), and neurostimulators, provide therapeutic interventions that were previously unavailable or less effective. The increasing prevalence of chronic diseases and age-related conditions, such as cardiovascular disorders, neurological disorders, and chronic pain, is fueling the demand for these devices. These devices offer long-term therapeutic solutions for managing chronic conditions, improving patient quality of life, and reducing healthcare costs associated with repeated hospitalizations and outpatient visits.

Furthermore, the shift towards minimally invasive procedures and outpatient care is driving the demand for active implanted medical devices. Advances in surgical techniques, implantable materials, and device miniaturization have made it possible to implant devices through minimally invasive procedures, reducing surgical risks, complications, and hospital stays. The growing emphasis on value-based healthcare and patient outcomes is driving the adoption of active implanted medical devices in hospitals. Healthcare providers are investing in state-of-the-art facilities, medical equipment, and electronic health record (EHR) systems to enhance patient care delivery and streamline clinical workflows. As hospitals continue to modernize and digitize their operations, the adoption of active implanted devices is likely to accelerate, further driving market growth.

Country/Region-wise Acumens

Which region has the most potential for growth of the Active Implanted Medical Devices Market?

The Asia-Pacific region is poised for significant growth in the active implanted medical devices market due to its diverse population, increasing healthcare expenditure, and technological advancements. The growing prevalence of chronic diseases and age-related conditions, such as cardiovascular disorders, neurological disorders, and diabetes, is expected to drive demand for advanced medical interventions. Governments in countries like China, India, and Japan are investing in healthcare infrastructure and improving quality, creating opportunities for active implanted device manufacturers to collaborate with healthcare providers and address unmet medical needs.

Technological advancements in the region, driven by leading medical device manufacturers, research institutions, and academic centers, are also driving the development of cutting-edge active implanted devices. The growing adoption of digital health solutions and telemedicine is also driving demand for active implanted devices that support remote monitoring, data integration, and connectivity with healthcare systems. Manufacturers offering devices with remote monitoring capabilities, interoperability, and data analytics are well-positioned to capitalize on the growing demand for connected healthcare solutions in the Asia-Pacific region.

Furthermore, the region's diverse market landscape, including developed economies and emerging markets, presents significant opportunities for market expansion. As manufacturers expand their presence and product offerings, they can capitalize on these diverse market opportunities and contribute to improved healthcare outcomes for millions of patients. The Asia-Pacific market is expected to emerge as a key growth engine for the global active implanted medical devices market in the coming years.

Which regions dominate in the Active Implanted Medical Devices Market?

North America is estimated to hold the largest market share during the forecast period. The region has a high level of healthcare spending, a strong regulatory environment, and a sophisticated healthcare infrastructure, all of which encourage the widespread use of active implanted devices.

Furthermore, A significant number of patients in North America suffer from age-related and chronic illnesses, which is fuelling the need for cutting-edge medical treatments like pacemakers, implanted cardioverter defibrillators (ICDs), and neurostimulators. The region's concentration of top medical device producers, research facilities, and academic institutions encourages technological innovation and product development, reinforcing North America's leadership in the market for active implanted medical devices.

Competitive Landscape

The competitive landscape in the active implanted medical devices market is dynamic and evolving, driven by changing customer preferences, technological advancements, and market dynamics. Providers continue to innovate and differentiate their offerings to stay competitive and capture market share in this rapidly growing market.

Some of the prominent players operating in the active implanted medical devices market include:

NeuroPace

Axonics

NEVRO CORP

BIOTRONIK

ABIOMED

Boston Scientific Corporation

Medtronic

Abbott

Eckert & Ziegler

Sonova Holding AG

Demant A/S

Cochlear Ltd

Microson S.A.U.

Oticon Medical A/S

Nano Retina

MED-EL Medical Electronics

Masimo

Hologic

Varian Medical Systems, Inc.

Latest Developments:

In August 2022, Medtronic plc launched an investigational extravascular implantable cardioverter defibrillator (EV ICD) system, achieving a defibrillation success rate of 98.7% in a global clinical trial. With the lead positioned under the breastbone, outside the heart and veins, this innovation marks a milestone in enhancing safety and efficacy in the active medical implantable devices market

In February 2022, Abbott initiated patient implants for its dual-chamber leadless pacemaker system, marking a technological breakthrough in leadless pacing. This milestone, part of the AVEIR DR i2i pivotal clinical study, represents the first occurrence globally within the trial, highlighting Abbott's advancements in active medical implantable devices and shaping future pacing technologies

In January 2021, Boston Scientific obtained FDA approval for its Vercise Deep Brain Stimulation System, comprising an implantable pulse generator for symptom relief. This approval marks an opportunity for the company to broaden its presence in the active medical implantable devices market, offering advanced solutions for neurological disorders and expanding its business prospects

In December 2020, Health Canada approved Abbott's FreeStyle Libre 2, offering continuous glucose monitoring with customizable alarms for adults and children with diabetes. This expansion into the active medical implantable devices market allows Abbott to diversify its offerings, catering to diabetic patients' needs and fostering growth opportunities in the future.

Active Implanted Medical Devices Market, by Category

Product Type:

Implantable Cardioverter Defibrillators

Ventricular Assist Devices

Implantable Heart Monitors

Implantable Cardiac Pacemakers

Implantable Hearing Devices

Neurostimulators

Others

End-user:

Hospitals

Clinics

Ambulatory Surgical Centers

Multi-Specialty Centers

Region:

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL ACTIVE IMPLANTED MEDICAL DEVICES MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL ACTIVE IMPLANTED MEDICAL DEVICES MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL ACTIVE IMPLANTED MEDICAL DEVICES MARKET, BY PRODUCT TYPE

• 5.1 Overview
• 5.2 Implantable Cardioverter Defibrillators
• 5.3 Ventricular Assist Devices
• 5.4 Implantable Heart Monitors
• 5.5 Implantable Cardiac Pacemakers
• 5.6 Implantable Hearing Devices
• 5.7 Neurostimulators
• 5.8 Others

6 GLOBAL ACTIVE IMPLANTED MEDICAL DEVICES MARKET, BY END-USER

• 6.1 Overview
• 6.2 Hospitals
• 6.3 Clinics
• 6.4 Ambulatory Surgical Centers
• 6.5 Multi-Specialty Centers
• 6.6 Others

7 GLOBAL ACTIVE IMPLANTED MEDICAL DEVICES MARKET, BY GEOGRAPHY

• 7.1 Overview
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 U.K.
  • 7.3.3 France
  • 7.3.4 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Rest of Asia Pacific
• 7.5 Middle East and Africa
• 7.6 Latin America

8 GLOBAL ACTIVE IMPLANTED MEDICAL DEVICES MARKET COMPETITIVE LANDSCAPE

• 8.1 Overview
• 8.2 Company Market Ranking
• 8.3 Key Development Strategies

9 COMPANY PROFILES

• 9.1 Boston Scientific Corporation
  • 9.1.1 Overview
  • 9.1.2 Financial Performance
  • 9.1.3 Product Outlook
  • 9.1.4 Key Developments
• 9.2 Medtronic Plc
  • 9.2.1 Overview
  • 9.2.2 Financial Performance
  • 9.2.3 Product Outlook
  • 9.2.4 Key Developments
• 9.3 William Demant Holding A/S
  • 9.3.1 Overview
  • 9.3.2 Financial Performance
  • 9.3.3 Product Outlook
  • 9.3.4 Key Developments
• 9.4 Abbott Laboratories
  • 9.4.1 Overview
  • 9.4.2 Financial Performance
  • 9.4.3 Product Outlook
  • 9.4.4 Key Developments
• 9.5 BIOTRONIK SE & Co. KG
  • 9.5.1 Overview
  • 9.5.2 Financial Performance
  • 9.5.3 Product Outlook
  • 9.5.4 Key Developments
• 9.6 Cochlear Limited
  • 9.6.1 Overview
  • 9.6.2 Financial Performance
  • 9.6.3 Product Outlook
  • 9.6.4 Key Developments
• 9.7 MED-EL
  • 9.7.1 Overview
  • 9.7.2 Financial Performance
  • 9.7.3 Product Outlook
  • 9.7.4 Key Developments
• 9.8 Sonova Holding AG
  • 9.8.1 Overview
  • 9.8.2 Financial Performance
  • 9.8.3 Product Outlook
  • 9.8.4 Key Developments
• 9.9 Nurotron Biotechnology Co., Ltd.
  • 9.9.1 Overview
  • 9.9.2 Financial Performance
  • 9.9.3 Product Outlook
  • 9.9.4 Key Developments
• 9.10 LivaNova PLC
  • 9.10.1 Overview
  • 9.10.2 Financial Performance
  • 9.10.3 Product Outlook
  • 9.10.4 Key Developments

10 Appendix

• 10.1.1 Related Research